BioStock: Alligator's CEO comments on restructuring plan

Alligator Bioscience is coming off a high after reaching the primary endpoint in the OPTIMIZE-1 phase II trial with lead candidate mitazalimab. However, together with their year-end report, Alligator announced a restructuring and cost-cutting plan. Alligator’s CEO Søren Bregenholt stopped by the BioStock studio to tells us more.

Watch the interview with Søren Bregenholt at BioStock.se

https://www.biostock.se/en/2024/02/alligators-ceo-comments-on-restructuring-plan/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/